In 2022, the combination of anti-PD-L1 durvalumab and anti-CTLA 4 tremelimumab showed promising results in the HIMALAYA trial and was positioned as first-line therapy for advanced HCC alongside Atz/Bev [46]. This evidence concerns the gene CD274 and hepatocellular carcinoma.